KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Financing Activities (2016 - 2025)

Arbutus Biopharma's Cash from Financing Activities history spans 13 years, with the latest figure at $844000.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 52.45% year-over-year to $844000.0; the TTM value through Sep 2025 reached $5.5 million, down 89.88%, while the annual FY2024 figure was $52.0 million, 69.66% up from the prior year.
  • Cash from Financing Activities for Q3 2025 was $844000.0 at Arbutus Biopharma, up from $453000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $59.1 million in Q4 2021 and bottomed at $113000.0 in Q2 2022.
  • The 5-year median for Cash from Financing Activities is $4.7 million (2023), against an average of $13.5 million.
  • The largest annual shift saw Cash from Financing Activities surged 4096.46% in 2023 before it plummeted 98.14% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $59.1 million in 2021, then plummeted by 81.25% to $11.1 million in 2022, then tumbled by 65.65% to $3.8 million in 2023, then tumbled by 62.67% to $1.4 million in 2024, then plummeted by 40.61% to $844000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Cash from Financing Activities are $844000.0 (Q3 2025), $453000.0 (Q2 2025), and $2.8 million (Q1 2025).